NCT04312399 Hormone Replacement Trial Against ALzheimers' Disease
| NCT ID | NCT04312399 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Ghent |
| Condition | Postmenopausal Symptoms |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2018-04-17 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 600 participants in total. It began in 2018-04-17 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The influence of postmenopausal hormone treatment on dementia is not clear. Dysfunctions in the metabolism of amyloid in the disease of Alzheimer result in an elevated presence of degradation products in cerebrospinal fluid. The degradation products in blood will be analysed during the trial, to get better insight in menopause and the start of hormonal therapy. Postmenopausal women with and without history of breast cancer will be recruited for the trial.
Eligibility Criteria
Inclusion Criteria: * postmenopausal women * 40 - 65 years Exclusion Criteria: * Longer than 10 years in menopause * thyroid dysfunction * hypertension * medical history of psychiatric comorbidity * Alcohol and/or drug abuse * medical history of neurologic symptoms with cognitive symptoms
Contact & Investigator
Herman Depypere, MD
PRINCIPAL INVESTIGATOR
University Hospital, Ghent
Frequently Asked Questions
Who can join the NCT04312399 clinical trial?
This trial is open to female participants only, aged 40 Years or older, up to 65 Years, studying Postmenopausal Symptoms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04312399 currently recruiting?
Yes, NCT04312399 is actively recruiting participants. Contact the research team at eline.meireson@uzgent.be for enrollment information.
Where is the NCT04312399 trial being conducted?
This trial is being conducted at Ghent, Belgium.
Who is sponsoring the NCT04312399 clinical trial?
NCT04312399 is sponsored by University Hospital, Ghent. The principal investigator is Herman Depypere, MD at University Hospital, Ghent. The trial plans to enroll 600 participants.